Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

diaDexus

diaDexus, a privately held biotechnology company, is focused on the discovery, development, and commercialization of novel, patent protected diagnostic products with high clinical value.
diaDexus’ lead product, the PLAC® test, is a blood test that measures the concentration of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel risk factor for coronary heart disease and ischemic stroke. The PLAC test was cleared for marketing by the FDA in July 2003 as in aid in determining risk for coronary heart disease. diaDexus also received marketing clearance for the PLAC test to aid in predicting risk for ischemic stroke associated with atherosclerosis in June 2005. Numerous published or presented studies, involving more than 9,000 subjects, highlight Lp-PLA2 as an important risk factor for cardiovascular disease.

diaDexus was formed in 1997 as a joint venture by SmithKline Beecham and Incyte. SmithKline Beecham granted diaDexus an exclusive license to certain diagnostic intellectual property, and Incyte contributed free access to its databases


Contact Details:
343 Oyster Point Blvd
South San Francisco
California
94080-1913
United States of America
Tel:650-246-6400
Fax:650-246-6499
Email:ir@diadexus.com
WWW:

www.diadexus.com/




Loading...

Recent Publications by diaDexus:

Enhancing the secretion of recombinant proteins by engineering N-glycosylation sites.
N-glycosylation is important for the folding and quality control of...
29th July, 2009
Dept. of Protein Science, diaDexus, Inc., South San Francisco, CA 94080, Biotechnol Prog. 2009 Sep-Oct;25(5):1468-75.
DOI Direct Link
Biomarkers for cardiovascular risk assessment.
N-glycosylation is important for the folding and quality control of...
17th June, 2009
DiaDexus Inc., South San Francisco, USA. MLO Med Lab Obs. 2009 May;41(5):14-6.
B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
OBJECTIVE: This study characterizes the expression of the novel biomarker...
7th September, 2007
diaDexus, Inc., 343 Oyster Point Blvd., South San Francisco, CA, USA. Gynecol Oncol. 2007 Aug;106(2):334-41. Epub 2007 May 11.
DOI Direct Link
Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
OBJECTIVE: Early detection through regular screening could significantly...
1st August, 2007
diaDexus, Inc., 343 Oyster Point Blvd., South San Francisco, CA 94080, Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8.
DOI Direct Link
How does hepatitis C virus enter cells?
Hepatitis C virus (HCV) exists in different forms in the circulation of...
18th October, 2006
diaDexus Inc., South FEBS J. 2006 Sep;273(17):3871-85.
DOI Direct Link

View more diaDexus research publications.

Press Releases on diaDexus:

BioPortfolio Logo
Reportlinker Adds Cholesterol and Other Cardiovascular Testing - Trends & Opportunities Worldwide 25th November, 2009 Reportlinker
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cholesterol and Other Cardiovascular Testing - Trends & Opportunities
diaDexus Announces Data on Lp-PLA2 to be Presented at International Symposium on Atherosclerosis 16th June, 2009 diaDexus, Inc.
Study Finds Lp-PLA2 is Reduced by About One-Third in Patients Receiving Lifestyle Intervention and Drug Therapy and that Changes in Lp-PLA2 are Only Slightly Related to Changes in LDL-C SOUTH SAN
Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 24th February, 2009 Axial Biotech, Inc.
Respected Researcher Provides Extensive Experience In Molecular Diagnostics SALT LAKE CITY, Feb. 24 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development
diaDexus Appoints Physicians Sales & Service to Distribute the PLAC(R) Test to Physician's Office Labs 27th August, 2008 diaDexus, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire/ -- diaDexus, Inc. today announced the appointment of Physicians Sales & Service, Inc. (PSS) as distributors of the PLAC Test to physician

diaDexus Patents:

US Patent No.Title
7560531 Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers
6949339 Method of diagnosing, monitoring, and staging colon cancer
6902892 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
6902890 Method of diagnosing monitoring, staging, imaging and treating cancer
6869592 Method and antibody for imaging lung cancer

View more diaDexus patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 255 times since April 2007, the link to the organisation's website has been followed 47 times

Recent Search Terms used to find this page: diadexu california | .

Search for more companies in South San Francisco

Search for more companies in California



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for diaDexus

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.